-
Innovation Ranking
Innovation Ranking – 10X Genomics Inc
10X Genomics Inc (10X Genomics) is engaged in developing an innovative genomics platform. The company’s product pipeline comprises chromium X series, chromium connect, and chromium controller. It offers services such as single-cell gene expression, single-cell immune profiling, fixed RNA profiling, single-cell multiome ATAC + gene expression, spatial gene expression, and targeted gene expression. The company also provides Barcode technology which is compatible with Single Cell Gene Expression and Immune Profiling solutions allowing researchers to simultaneously measure multiple analytes, such as...
-
Innovation Ranking
Innovation Ranking – BioNano Genomics Inc
BioNano Genomics Inc (BioNano) is a developer of technology platform to analyze the segments of genomic DNA and other structural variations. The company's products include Saphyr optical genome mapping instrument, bionano chips, bionano sample prep kits and bionano data solutions. BioNano’s prep kits are optimized to extract and label DNA for genome mapping systems. The company also offers data solutions which provide experiment management, analysis, and bioinformatics processing. It conducts research across various areas including human disease, agricultural bioengineering and...
-
Innovation Ranking
Innovation Ranking – BGI Genomics Co Ltd
BGI Genomics Co Ltd (BGI Genomics), a subsidiary of Beijing BGI-GBI Biotech Co Ltd BGI, provides next generation sequencing services and genetic tests. The company offers services including DNA (deoxyribonucleic acid) sequencing, RNA (ribonucleic acid) sequencing, non-invasive prenatal testing, newborn genetic screening, reproductive health screening, customized sequencing services and clinical exome sequencing services. BGI Genomics also conducts research to advance precision medicine and diagnostics in the fields of metagenomics, reproductive health and for detecting cancer. It serves various medical institutions,...
-
Product Insights
NewNet Present Value Model: Oryzon Genomics SA’s Vafidemstat
Empower your strategies with our Net Present Value Model: Oryzon Genomics SA's Vafidemstat report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Sector Analysis
NewFuture of Pharma – Looking Ahead to 2024
This report provides a summary of the near and long-term future of the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot and prioritize them within your sectors.
-
Product Insights
Likelihood of Approval Analysis for Hepadnaviridae Infections
Overview How likely is it that the drugs in Hepadnaviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hepadnaviridae Infections Overview Hepadnaviridae infections are caused by a family of viruses...
-
Thematic Analysis
NewMedical Devices M&A Deals, Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Medical Devices Sector
-
Product Insights
Likelihood of Approval Analysis for Retroviridae Infections
Overview How likely is it that the drugs in Retroviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Retroviridae Infections Overview Retroviruses belong to a family of enveloped RNA viruses...
-
Product Insights
Likelihood of Approval Analysis for Rhabdoviridae Infections
Overview How likely is it that the drugs in Rhabdoviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhabdoviridae Infections Overview The family Rhabdoviridae are negatively stranded RNA viruses consisting...